ALPS Advisors’s Cullinan Oncology CGEM Stock Holding History

ALPS Advisors’s Portfolio CGEM Stock Details CGEM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-24,941	Closed	-$320K	–	1036
2022 Q3	$320K	Sell	24,941 -1,624	-6%	-$21.9K	﹤0.01%	693
2022 Q2	$341K	Buy	+26,565	New	+$301K	﹤0.01%	708

Other funds holding CGEM

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

American International Group New York $609M AUM 23.67% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

ALPS Advisors's CGEM Position: Q4 2022 in Review

ALPS Advisors sold out of Cullinan Oncology (CGEM) in Q4 2022, closing a stake of 24,941 shares — an estimated $320K sold.

ALPS Advisors first reported a position in CGEM in Q2 2022 and held it in 2 quarters. The position peaked at $341K in Q2 2022. 97 funds tracked by Wall St. Rank hold CGEM as of Q4 2022.

ALPS Advisors reported no remaining Cullinan Oncology position as of Q4 2022 after selling out during the quarter.
ALPS Advisors sold 24,941 Cullinan Oncology shares in Q4 2022, an estimated $320K.
ALPS Advisors first reported a position in Cullinan Oncology in Q2 2022 and held it in 2 quarters.
ALPS Advisors's Cullinan Oncology position peaked at $341K in Q2 2022.
97 funds tracked by Wall St. Rank held Cullinan Oncology as of Q4 2022.

Based on ALPS Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.